Digital gastrointestinal care startup salvo health Announced that it has closed a $5 million Seed Prime round led by City Light Capital and Human Ventures.
Existing investors also participated in the round, including Torch Capital, Threshold Ventures, and Felicis Ventures. Angel investors Anmol Madan, founder of Ginger Health and former chief data scientist at Teladoc, also contributed.
Threshold's Emily Melton, City Light's Rachel Parlier, and Salvo founder and CEO Jeffrey Glueck will join Salvo's board of directors.
function
The New York-based company deals with chronic gastrointestinal and metabolic liver problems such as celiac disease, fatty liver disease, irritable bowel syndrome (IBS), gastroesophageal reflux disease (GERD), and small intestinal bacterial overgrowth (SIBO). We offer virtual clinics for people. and indigestion.
The company says it will provide „wraparound care“ with a hybrid approach, allowing patients to continue with their local physician and access Salvo's app-based support.
Through Salvo, users are matched with a care team of registered dietitians, behavioral health professionals, and certified nurses to receive insurance-covered multidisciplinary care.
The company plans to use the funding to expand its wraparound GI services to healthcare providers, including accountable care organizations, gastroenterology practitioners, and health systems.
„We are excited to invest in Salvo Health and to lead the company's innovative comprehensive care for gastrointestinal and metabolic chronic diseases,“ said City Light Capital's Parlier in a statement. “As early-stage impact investors, we look for companies that have the potential to not only transform industries, but also improve lives. „It allows us to fill a gap in underserved patient populations, especially those with advanced disease. We also touch on follow-up care between appointments and procedures.“
market snapshot
Salvo was founded in 2022 with $10.5 million in funding to expand its virtual clinic for chronic gastrointestinal diseases.
Other companies participating in the virtual gastrointestinal care space include: Vivante Healthhas been secured $31 million in funding in September, and Oshi healthobtained $30 million in Series B funding During April.
“Streamlining AI-Enabled Digital Health Technologies from Research to Implementation” is scheduled to take place on Tuesday, March 12th from 1:30-2:30pm ET at HIMSS24 in Orlando, W304A. Details and registration.